[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f6d_IM4O3i1fgTeSuvZlUFJ_gZcLKmlIIvnnzgRjHSnc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":31,"phaseBuckets":37,"rows":44},"Imperial College Healthcare NHS Trust",[4],78,false,9,1,158316,61,[13,16,18,21,23,25,27,29],{"name":14,"count":15},"Blood Pressure",3,{"name":17,"count":15},"Covid19",{"name":19,"count":20},"Hypoactive Sexual Desire Disorder",2,{"name":22,"count":20},"Lung Cancer",{"name":24,"count":20},"Peripheral Arterial Disease",{"name":26,"count":20},"Peripheral Artery Disease",{"name":28,"count":20},"Anesthesia",{"name":30,"count":20},"Tuberculosis",[32],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT05870150","Challenge Non-Typhoidal Salmonella (CHANTS) Study","2026-02-28","Salmonella Typhimurium",[38,39,40,41,42,43],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[45,74,126,155,173,196,223,241,265,283,308,333,360,378,405,431,449,481,499,524,551],{"intervention":36,"totalTrials":9,"cells":46},{"EARLY_PHASE1":47,"PHASE1":50,"PHASE2":52,"PHASE3":54,"PHASE4":56,"NA":58},{"trials":48,"activeCount":49},[],0,{"trials":51,"activeCount":49},[],{"trials":53,"activeCount":49},[],{"trials":55,"activeCount":49},[],{"trials":57,"activeCount":49},[],{"trials":59,"activeCount":9,"soonestReadout":35},[60],{"nctId":33,"briefTitle":34,"status":61,"phases":62,"primaryCompletion":35,"completion":35,"start":63,"enrollment":64,"conditions":65,"interventions":73},"ACTIVE_NOT_RECRUITING",[43],"2023-08-31",80,[66,36,67,68,69,70,71,72],"Salmonella Infections","Non-typhoidal Salmonella (NTS)","Invasive Non-Typhoidal Salmonella Disease","Communicable Disease","Infections, Bacterial","Enteric Fever (Not Typhoid)","Gastroenteritis",[36],{"intervention":75,"totalTrials":15,"cells":76},"tacrolimus",{"EARLY_PHASE1":77,"PHASE1":79,"PHASE2":81,"PHASE3":83,"PHASE4":85,"NA":124},{"trials":78,"activeCount":49},[],{"trials":80,"activeCount":49},[],{"trials":82,"activeCount":49},[],{"trials":84,"activeCount":49},[],{"trials":86,"activeCount":49},[87,99,111],{"nctId":88,"briefTitle":89,"status":90,"phases":91,"primaryCompletion":92,"completion":92,"start":93,"enrollment":94,"conditions":95,"interventions":97},"NCT00982072","Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease","COMPLETED",[42],"2019-10-10","2009-12",52,[96],"Minimal Change Disease",[75,98],"prednisolone",{"nctId":100,"briefTitle":101,"status":90,"phases":102,"primaryCompletion":103,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":109},"NCT00843856","Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis",[42],"2018-03","2018-09-18","2009-03-03",40,[108],"Glomerulonephritis, Membranous",[75,110],"tacrolimus and mycophenolate mofetil",{"nctId":112,"briefTitle":113,"status":90,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":121},"NCT00807144","Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation",[42],"2012-03","2008-12",102,[119,120],"End-stage Renal Failure","Graft Rejection",[122,123],"Tacrolimus","Kidney transplant maintenance immunosuppression",{"trials":125,"activeCount":49},[],{"intervention":127,"totalTrials":9,"cells":128},"Envarsus Oral Product",{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":137,"NA":153},{"trials":130,"activeCount":49},[],{"trials":132,"activeCount":49},[],{"trials":134,"activeCount":49},[],{"trials":136,"activeCount":49},[],{"trials":138,"activeCount":49},[139],{"nctId":140,"briefTitle":141,"status":142,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":152},"NCT03689075","Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation","TERMINATED",[42],"2024-06-27","2025-02-25","2018-11-01",35,[149,150,151],"Kidney Transplant Failure","Allosensitization","Immunosuppression",[127],{"trials":154,"activeCount":49},[],{"intervention":98,"totalTrials":9,"cells":156},{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":165,"NA":171},{"trials":158,"activeCount":49},[],{"trials":160,"activeCount":49},[],{"trials":162,"activeCount":49},[],{"trials":164,"activeCount":49},[],{"trials":166,"activeCount":49},[167],{"nctId":88,"briefTitle":89,"status":90,"phases":168,"primaryCompletion":92,"completion":92,"start":93,"enrollment":94,"conditions":169,"interventions":170},[42],[96],[75,98],{"trials":172,"activeCount":49},[],{"intervention":174,"totalTrials":9,"cells":175},"Bremelanotide",{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":180,"PHASE3":182,"PHASE4":184,"NA":194},{"trials":177,"activeCount":49},[],{"trials":179,"activeCount":49},[],{"trials":181,"activeCount":49},[],{"trials":183,"activeCount":49},[],{"trials":185,"activeCount":49},[186],{"nctId":187,"briefTitle":188,"status":90,"phases":189,"primaryCompletion":190,"completion":190,"start":191,"enrollment":106,"conditions":192,"interventions":193},"NCT04179734","Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder",[42],"2020-10-06","2019-10-07",[19],[174],{"trials":195,"activeCount":49},[],{"intervention":197,"totalTrials":9,"cells":198},"Evolocumab Auto-Injector [Repatha]",{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":205,"PHASE4":207,"NA":221},{"trials":200,"activeCount":49},[],{"trials":202,"activeCount":49},[],{"trials":204,"activeCount":49},[],{"trials":206,"activeCount":49},[],{"trials":208,"activeCount":49},[209],{"nctId":210,"briefTitle":211,"status":212,"phases":213,"primaryCompletion":214,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":220},"NCT03931161","Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)","UNKNOWN",[42],"2023-05-06","2024-05-06","2019-09-04",33,[219],"Carotid Artery Stenosis",[197],{"trials":222,"activeCount":49},[],{"intervention":110,"totalTrials":9,"cells":224},{"EARLY_PHASE1":225,"PHASE1":227,"PHASE2":229,"PHASE3":231,"PHASE4":233,"NA":239},{"trials":226,"activeCount":49},[],{"trials":228,"activeCount":49},[],{"trials":230,"activeCount":49},[],{"trials":232,"activeCount":49},[],{"trials":234,"activeCount":49},[235],{"nctId":100,"briefTitle":101,"status":90,"phases":236,"primaryCompletion":103,"completion":104,"start":105,"enrollment":106,"conditions":237,"interventions":238},[42],[108],[75,110],{"trials":240,"activeCount":49},[],{"intervention":242,"totalTrials":9,"cells":243},"Intrinsa Transdermal testosterone patch",{"EARLY_PHASE1":244,"PHASE1":246,"PHASE2":248,"PHASE3":250,"PHASE4":252,"NA":263},{"trials":245,"activeCount":49},[],{"trials":247,"activeCount":49},[],{"trials":249,"activeCount":49},[],{"trials":251,"activeCount":49},[],{"trials":253,"activeCount":49},[254],{"nctId":255,"briefTitle":256,"status":90,"phases":257,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":262},"NCT01208038","Testosterone Patch's Effects on the Cardiovascular System and Libido",[42],"2012-02","2011-03",22,[19],[242],{"trials":264,"activeCount":49},[],{"intervention":123,"totalTrials":9,"cells":266},{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":271,"PHASE3":273,"PHASE4":275,"NA":281},{"trials":268,"activeCount":49},[],{"trials":270,"activeCount":49},[],{"trials":272,"activeCount":49},[],{"trials":274,"activeCount":49},[],{"trials":276,"activeCount":49},[277],{"nctId":112,"briefTitle":113,"status":90,"phases":278,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":279,"interventions":280},[42],[119,120],[122,123],{"trials":282,"activeCount":49},[],{"intervention":284,"totalTrials":9,"cells":285},"sodium bicarbonate 500mg",{"EARLY_PHASE1":286,"PHASE1":288,"PHASE2":290,"PHASE3":292,"PHASE4":294,"NA":306},{"trials":287,"activeCount":49},[],{"trials":289,"activeCount":49},[],{"trials":291,"activeCount":49},[],{"trials":293,"activeCount":49},[],{"trials":295,"activeCount":49},[296],{"nctId":297,"briefTitle":298,"status":90,"phases":299,"primaryCompletion":300,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":305},"NCT02692378","Effects of Oral Sodium Bicarbonate Supplementation in Haemodialysis Patients (BicHD)",[42],"2016-05","2015-11",44,[304],"End-stage Renal Disease",[284],{"trials":307,"activeCount":49},[],{"intervention":309,"totalTrials":9,"cells":310},"Ketamine",{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":319,"NA":331},{"trials":312,"activeCount":49},[],{"trials":314,"activeCount":49},[],{"trials":316,"activeCount":49},[],{"trials":318,"activeCount":49},[],{"trials":320,"activeCount":49},[321],{"nctId":322,"briefTitle":323,"status":90,"phases":324,"primaryCompletion":325,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":330},"NCT01296347","Low Dose Peri-operative IV Ketamine for Chronic Post-surgery Pain Prevention",[42],"2015-07","2011-04",77,[329],"Chronic Postoperative Pain",[309],{"trials":332,"activeCount":49},[],{"intervention":334,"totalTrials":9,"cells":335},"Iron sucrose",{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":340,"PHASE3":342,"PHASE4":344,"NA":358},{"trials":337,"activeCount":49},[],{"trials":339,"activeCount":49},[],{"trials":341,"activeCount":49},[],{"trials":343,"activeCount":49},[],{"trials":345,"activeCount":49},[346],{"nctId":347,"briefTitle":348,"status":90,"phases":349,"primaryCompletion":350,"completion":351,"start":325,"enrollment":352,"conditions":353,"interventions":356},"NCT02707757","Treatment Response in Dialysis Anaemia",[42],"2016-12","2017-04",197,[354,355],"Anaemia","Haemodialysis",[334,357],"Erythopoietin stimulating agent",{"trials":359,"activeCount":49},[],{"intervention":357,"totalTrials":9,"cells":361},{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":368,"PHASE4":370,"NA":376},{"trials":363,"activeCount":49},[],{"trials":365,"activeCount":49},[],{"trials":367,"activeCount":49},[],{"trials":369,"activeCount":49},[],{"trials":371,"activeCount":49},[372],{"nctId":347,"briefTitle":348,"status":90,"phases":373,"primaryCompletion":350,"completion":351,"start":325,"enrollment":352,"conditions":374,"interventions":375},[42],[354,355],[334,357],{"trials":377,"activeCount":49},[],{"intervention":379,"totalTrials":9,"cells":380},"Obeticholic acid",{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":399,"PHASE4":401,"NA":403},{"trials":382,"activeCount":49},[],{"trials":384,"activeCount":49},[],{"trials":386,"activeCount":49},[387],{"nctId":388,"briefTitle":389,"status":90,"phases":390,"primaryCompletion":391,"completion":392,"start":393,"enrollment":147,"conditions":394,"interventions":398},"NCT01585025","Obeticholic Acid in Bile Acid Diarrhoea",[40],"2014-01","2014-02","2012-04",[395,396,397],"Primary Bile Acid Malabsorption","Secondary Bile Acid Malabsorption","Chronic Diarrhoea",[379],{"trials":400,"activeCount":49},[],{"trials":402,"activeCount":49},[],{"trials":404,"activeCount":49},[],{"intervention":406,"totalTrials":9,"cells":407},"Shortened hydration time and dispensary of Akynzeo",{"EARLY_PHASE1":408,"PHASE1":410,"PHASE2":412,"PHASE3":425,"PHASE4":427,"NA":429},{"trials":409,"activeCount":49},[],{"trials":411,"activeCount":49},[],{"trials":413,"activeCount":49},[414],{"nctId":415,"briefTitle":416,"status":212,"phases":417,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":421,"interventions":423},"NCT04362449","Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration",[40],"2023-02-02","2019-01-02",30,[422],"Gallbladder Cancer",[406,424],"Standard of care",{"trials":426,"activeCount":49},[],{"trials":428,"activeCount":49},[],{"trials":430,"activeCount":49},[],{"intervention":424,"totalTrials":9,"cells":432},{"EARLY_PHASE1":433,"PHASE1":435,"PHASE2":437,"PHASE3":443,"PHASE4":445,"NA":447},{"trials":434,"activeCount":49},[],{"trials":436,"activeCount":49},[],{"trials":438,"activeCount":49},[439],{"nctId":415,"briefTitle":416,"status":212,"phases":440,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":441,"interventions":442},[40],[422],[406,424],{"trials":444,"activeCount":49},[],{"trials":446,"activeCount":49},[],{"trials":448,"activeCount":49},[],{"intervention":450,"totalTrials":9,"cells":451},"BMS-986414",{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":475,"PHASE4":477,"NA":479},{"trials":453,"activeCount":49},[],{"trials":455,"activeCount":49},[],{"trials":457,"activeCount":49},[458],{"nctId":459,"briefTitle":460,"status":461,"phases":462,"primaryCompletion":463,"completion":463,"start":464,"enrollment":49,"conditions":465,"interventions":473},"NCT05393999","SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations","WITHDRAWN",[40],"2022-03-04","2021-11-29",[466,467,468,469,470,471,472],"SARS-CoV2 Infection","SARS-CoV-2 Acute Respiratory Disease","Myeloma","Leukemia","Lymphoma","Immune Thrombocytopenia","Thrombotic Thrombocytopenic Purpura (TTP)",[450,474],"BMS-986413",{"trials":476,"activeCount":49},[],{"trials":478,"activeCount":49},[],{"trials":480,"activeCount":49},[],{"intervention":474,"totalTrials":9,"cells":482},{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":493,"PHASE4":495,"NA":497},{"trials":484,"activeCount":49},[],{"trials":486,"activeCount":49},[],{"trials":488,"activeCount":49},[489],{"nctId":459,"briefTitle":460,"status":461,"phases":490,"primaryCompletion":463,"completion":463,"start":464,"enrollment":49,"conditions":491,"interventions":492},[40],[466,467,468,469,470,471,472],[450,474],{"trials":494,"activeCount":49},[],{"trials":496,"activeCount":49},[],{"trials":498,"activeCount":49},[],{"intervention":500,"totalTrials":9,"cells":501},"Nuc-1031 and Carboplatin",{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":516,"PHASE3":518,"PHASE4":520,"NA":522},{"trials":503,"activeCount":49},[],{"trials":505,"activeCount":49},[506],{"nctId":507,"briefTitle":508,"status":90,"phases":509,"primaryCompletion":510,"completion":510,"start":511,"enrollment":512,"conditions":513,"interventions":515},"NCT02303912","Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer",[39],"2017-01-23","2014-11",25,[514],"Recurrent Ovarian Cancer",[500],{"trials":517,"activeCount":49},[],{"trials":519,"activeCount":49},[],{"trials":521,"activeCount":49},[],{"trials":523,"activeCount":49},[],{"intervention":525,"totalTrials":9,"cells":526},"Live attenuated influenza vaccine",{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":533,"PHASE4":535,"NA":537},{"trials":528,"activeCount":49},[],{"trials":530,"activeCount":49},[],{"trials":532,"activeCount":49},[],{"trials":534,"activeCount":49},[],{"trials":536,"activeCount":49},[],{"trials":538,"activeCount":49},[539],{"nctId":540,"briefTitle":541,"status":90,"phases":542,"primaryCompletion":543,"completion":544,"start":545,"enrollment":546,"conditions":547,"interventions":550},"NCT04110366","Nasal and Systemic Immune Responses to Nasal Influenza Vaccine",[43],"2019-04-04","2020-05-29","2018-06-14",48,[548,549],"Influenza","Vaccine Virus Shedding",[525],{"intervention":552,"totalTrials":9,"cells":553},"Golimumab",{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":562,"NA":564},{"trials":555,"activeCount":49},[],{"trials":557,"activeCount":49},[],{"trials":559,"activeCount":49},[],{"trials":561,"activeCount":49},[],{"trials":563,"activeCount":49},[],{"trials":565,"activeCount":49},[566],{"nctId":567,"briefTitle":568,"status":142,"phases":569,"primaryCompletion":570,"completion":570,"start":571,"enrollment":572,"conditions":573,"interventions":575},"NCT02841176","Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis",[43],"2017-09-19","2016-07",4,[574],"Psoriatic Arthritis",[552]]